J Thromb Haemost:慢性免疫性血小板减少症患者心血管和出血结局

2019-04-05 xing.T 网络

在cITP患者中,心血管事件的1年风险为1%-2%,而近1%的患者在1年内出现了出血事件。各种血小板水平均发生心血管事件,而低血小板计数与出血危害增加有关。心血管和出血事件是死亡率的强预后因素。

在患有慢性免疫性血小板减少症(cITP)的患者中,关于血管和出血结局的危险因素以及这些事件如何影响死亡率的知识很少。近日,血栓和凝血疾病权威杂志Journal of Thrombosis and Haemostasis上发表了一篇研究文章,研究人员根据血小板计数水平评估了需要医院诊疗血管事件和出血发生率,以及这些事件对成人cITP患者全因死亡率的预后影响。

研究人员确定了1996-2015年期间在北欧国家患者登记处登记的所有cITP患者,并计算了基于Cox回归分析的血小板计数水平的绝对风险和风险比,调整了年龄、性别、cITP患病率和发病率、吸烟和合并症。研究人员还比较了伴有和没有心血管和出血事件的cITP患者的全因死亡率。

在3584例cITP患者中,动脉血管事件的1年风险为1.9%,静脉血栓栓塞为1.2%,出血为7.5%。血小板计数的心血管事件发生率相似。血小板计数<50×109/L的患者出血率比血小板计数正常的患者高2倍以上。这些关联在随时间变化的分析中保持不变,该分析考虑了随访期间血小板计数的变化。心血管和出血事件的发生与1年死亡率的增加相关,增加了4到5倍。

在cITP患者中,心血管事件的1年风险为1%-2%,而近1%的患者在1年内出现了出血事件。各种血小板水平均发生心血管事件,而低血小板计数与出血危害增加有关。心血管和出血事件是死亡率的强预后因素。

原始出处:

Kasper Adelborg.et al.Cardiovascular and bleeding outcomes in a population‐based cohort of patients with chronic immune thrombocytopenia.Journal of Thrombosis and Haemostasis.2019.https://onlinelibrary.wiley.com/doi/10.1111/jth.14446

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008415, encodeId=138d200841558, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Jun 20 14:59:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754076, encodeId=df4b1e540763f, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Jun 13 00:59:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302818, encodeId=ea96130281858, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Apr 07 01:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
    2019-06-20 changfy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2008415, encodeId=138d200841558, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Jun 20 14:59:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754076, encodeId=df4b1e540763f, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Jun 13 00:59:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302818, encodeId=ea96130281858, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Apr 07 01:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2008415, encodeId=138d200841558, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Jun 20 14:59:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754076, encodeId=df4b1e540763f, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Jun 13 00:59:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302818, encodeId=ea96130281858, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sun Apr 07 01:59:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]

相关资讯

Lacnet:艾曲波帕对慢性免疫性血小板减少症儿童患者是有效的

对患有慢性免疫性血小板减少症的成年患者,促血小板生成素受体激动剂艾曲波帕被证明是安全、可耐受、且有效的。研究者进行了一项研究(PETIT2),探究该药物对慢性免疫性血小板减少症的儿童患者的安全性和有效性。PETIT2是在12个国家38个中心进行的随机、多中心、安慰剂对照试验。参与者为1-17岁慢性免疫性血小板减少症患者,其血小板计数低于30 × 109 /L,将其随机分为艾曲波帕组和对照组。研究者